# EDGAR Filing Document

**Accession Number:** 0001178253
**File Stem:** 0000950170-25-092176
**Filing Date:** 2025-7
**Character Count:** 6682
**Document Hash:** 7766308944299749f53c4698751eaf3f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-092176.hdr.sgml**: 20250701

**ACCESSION NUMBER**: 0000950170-25-092176

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250625

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250701

**DATE AS OF CHANGE**: 20250701

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SCYNEXIS INC
- **CENTRAL INDEX KEY:** 0001178253
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 562181648
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36365
- **FILM NUMBER:** 251096202

**BUSINESS ADDRESS:**
- **STREET 1:** 1 EVERTRUST PLAZA
- **STREET 2:** 13TH FLOOR
- **CITY:** JERSEY CITY
- **STATE:** NJ
- **ZIP:** 07302-6548
- **BUSINESS PHONE:** 201-884-5485

**MAIL ADDRESS:**
- **STREET 1:** 1 EVERTRUST PLAZA
- **STREET 2:** 13TH FLOOR
- **CITY:** JERSEY CITY
- **STATE:** NJ
- **ZIP:** 07302-6548

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 25, 2025<br>

------

SCYNEXIS, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-36365 | 56-2181648 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 1 Evertrust Plaza<br>13th Floor |  |  |
| Jersey City**,** New Jersey |  | 07302-6548 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 201 884-5485<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | SCYX | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## **Item 5.07 Submission of Matters to a Vote of Security Holders.** 
On June 25, 2025, SCYNEXIS, Inc. held its 2025 Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast: (a) for or withheld with respect to the election of directors; (b) for, against or abstain for the ratification of the appointment of Deloitte & Touche LLP as SCYNEXIS's independent registered public accounting firm for the fiscal year ending December 31, 2025; and (c) for, against or abstain for the advisory approval of the executive compensation as disclosed in SCYNEXIS's proxy statement, filed with the Securities and Exchange Commission on April 30, 2025 (the "Proxy Statement").

---

| | | | |
|:---|:---|:---|:---|
| Proposal 1: | Each of the seven directors proposed by SCYNEXIS for re-election was elected to serve until SCYNEXIS's 2026 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified. The tabulation of votes on this matter was as follows:  | Each of the seven directors proposed by SCYNEXIS for re-election was elected to serve until SCYNEXIS's 2026 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified. The tabulation of votes on this matter was as follows:  | Each of the seven directors proposed by SCYNEXIS for re-election was elected to serve until SCYNEXIS's 2026 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified. The tabulation of votes on this matter was as follows:  |
|  | For | Withheld | Broker<br>Non-Votes |
| David Angulo, M.D. | 13412224 | 1121235 | 12473330 |
| Armando Anido | 13309055 | 1224404 | 12473330 |
| Steven C. Gilman, Ph.D. | 13065389 | 1468070 | 12473330 |
| Ann F. Hanham, Ph.D. | 13228680 | 1304779 | 12473330 |
| David Hastings | 13414768 | 1118691 | 12473330 |
| Guy Macdonald | 13213263 | 1320196 | 12473330 |
| Philippe Tinmouth | 13371338 | 1162121 | 12473330 |

---

---

| | |
|:---|:---|
| Proposal 2: | The appointment of Deloitte & Touche LLP as SCYNEXIS's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The tabulation of votes on this matter was as follows:  |

---

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker<br>Non-Votes |
| 25,543,125 | 797,439 | 666,225 |  |

---

---

| | |
|:---|:---|
| Proposal 3: | Advisory approval of the compensation of SCYNEXIS's named executive officers as disclosed in the Proxy Statement, was approved. The tabulation of votes on this matter was as follows: |

---

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker<br>Non-Votes |
| 12,417,323 | 1,425,389 | 690,747 | 12,473,330 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | SCYNEXIS, Inc. |
| Date: | July 1, 2025 | By:  | /s/ David Angulo, M.D. |
|  |  | Name:<br>Its:  | David Angulo, M.D.<br> Chief Executive Officer |

---

------